These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21590444)

  • 21. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
    Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
    Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
    Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
    Xu J; Zhou Y; Zhang J; Chen Y; Zhuang R; Liu T; Cai W
    Clin Chim Acta; 2012 Aug; 413(15-16):1284-7. PubMed ID: 22546611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
    Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
    [No Abstract]   [Full Text] [Related]  

  • 26. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Crul M; Schoemaker NE; Pluim D; Maliepaard M; Underberg RW; Schot M; Sparidans RW; Baas P; Beijnen JH; Van Zandwijk N; Schellens JH
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3526-33. PubMed ID: 14506138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
    Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
    Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
    Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
    Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
    Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
    Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
    Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer.
    Karacetin D; Incekara O
    J BUON; 2006; 11(2):181-4. PubMed ID: 17318968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
    Ryu JS; Kim HJ; Shin ES; Nam HS; Cho JH; Lee JE
    Oncol Res; 2012; 20(1):25-30. PubMed ID: 23035362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
    Bjånes TK; Jordheim LP; Schjøtt J; Kamceva T; Cros-Perrial E; Langer A; Ruiz de Garibay G; Kotopoulis S; McCormack E; Riedel B
    Drug Metab Dispos; 2020 Mar; 48(3):153-158. PubMed ID: 31871136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
    Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
    Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Rademaker-Lakhai JM; Crul M; Pluim D; Sparidans RW; Baas P; Beijnen JH; van Zandwijk N; Schellens JH
    Anticancer Drugs; 2005 Oct; 16(9):1029-36. PubMed ID: 16162981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Vivaldi C; Crucitta S; Catanese S; Cucchiara F; Arrigoni E; Pecora I; Rofi E; Fornaro L; Salani F; Massa V; Vasile E; Morganti R; Danesi R; Del Re M
    Pharmacogenomics J; 2021 Apr; 21(2):233-242. PubMed ID: 33462346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.